Our data show that mutation of VCP/p97 in IBMPFD disrupts mTOR signaling, a serine/threonine kinase that contributes to myopathy and which has been showing to worsen the severity of the disease (18) (Figure 4B). Here, MARK2 is linked to myopathy.